These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9092035)

  • 1. [Amphotericin B deoxycholate (Fungizone): old drug, new versions].
    Chavanet P
    Rev Med Interne; 1997; 18(2):153-65. PubMed ID: 9092035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
    Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA
    J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ; Vulto AG; Van Etten EW
    J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amphotericin B deoxycholate (Fungizone): old drug, new versions].
    Chavanet P
    Rev Med Interne; 1996; 17 Suppl 3():349s-353s. PubMed ID: 9008743
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
    Heinemann V; Bosse D; Jehn U; Kähny B; Wachholz K; Debus A; Scholz P; Kolb HJ; Wilmanns W
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1275-80. PubMed ID: 9174183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.
    Pallister CJ; Johnson EM; Warnock DW; Elliot PJ; Reeves DF
    J Antimicrob Chemother; 1992 Sep; 30(3):313-20. PubMed ID: 1452496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of high-dose liposomal amphotericin B: efficacy and tolerance.
    Garbino J; Adam A
    Acta Biomed; 2006; 77 Suppl 4():19-22. PubMed ID: 17370566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):899-902. PubMed ID: 9559804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin B--not so terrible.
    Bishara J; Weinberger M; Lin AY; Pitlik S
    Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
    Henderson RJ; Leon CG; Wasan KM
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products.
    Liu Y; Mei Z; Mei L; Tang J; Yuan W; Srinivasan S; Ackermann R; Schwendeman AS
    Eur J Pharm Biopharm; 2020 Dec; 157():241-249. PubMed ID: 32980448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the lipid formulations of amphotericin B.
    Dupont B
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.
    Echevarría I; Barturen C; Renedo MJ; Trocóniz IF; Dios-Viéitez MC
    Antimicrob Agents Chemother; 2000 Apr; 44(4):898-904. PubMed ID: 10722488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of nebulised amphotericin B deoxycholate (Fungizone
    Otu AA; Langridge P; Denning DW
    Mycoses; 2019 Nov; 62(11):1049-1055. PubMed ID: 31479538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B and its delivery by liposomal and lipid formulations.
    Gates C; Pinney RJ
    J Clin Pharm Ther; 1993 Jun; 18(3):147-53. PubMed ID: 8344999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.